rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ARQT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Arcutis Biotherapeutics (ARQT) Stock Looks Expensive Despite Its Huge Three Year Run
      Nov 14Yahoo FinanceARQT
      Arcutis reports trial data on infant eczema treatment candidate
      Nov 13Investing.comARQT
      Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ...
      Nov 7Yahoo FinanceARQT
      Arcutis Biotherapeutics (ARQT) Raised 2026 Sales Guidance, Is The Upside Already Priced In?

      Arcutis Biotherapeutics (ARQT) drew investor attention after reporting third quarter 2026 earnings, with net product revenue for ZORYVE up 45% year over year and full year sales guidance nudged higher. The reaction in Arcutis Biotherapeutics’ share price has been sharp, with the stock falling about 20.7% on the day and 15.8% over the past week. This comes even though the 30 day share price return is up 11.7% and the 1 year total shareholder return sits at 11.4%. The very large 3 year total...

      Nov 6Yahoo FinanceARQT
      Arcutis stock falls after Q3 earnings miss (ARQT:NASDAQ)

      Arcutis Biotherapeutics (ARQT) stock plunges as the company's Q3 2026 earnings falls short of forecasts amid higher costs. Read more here.

      Nov 5Seeking AlphaARQT
      Arcutis Biotherapeutics, Inc. Q3 2026 Earnings Call Summary
      Nov 5Yahoo FinanceARQT
      Arcutis Biotherapeutics EVP, CMO, sells $30,047 in shares
      Nov 5Investing.comARQT
      Arcutis Biotherapeutics CEO Todd Watanabe sells $139,466 in stock
      Nov 5Investing.comARQT
      Arcutis Biotherapeutics Q3 Earnings Call Highlights
      Nov 5Yahoo FinanceARQT
      Arcutis Biotherapeutics Q3 2026 Earnings Call Transcript
      Nov 4BenzingaARQT
      Arcutis earnings missed by $0.12, revenue topped estimates
      Nov 4Investing.comARQT
      Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates
      Nov 4Yahoo FinanceARQT
      Arcutis earnings on deck: Can Zoryve growth offset seasonal drag?
      Nov 4Investing.comARQT
      Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Q3 2026 -- GF Value Sees 35% Upside
      Nov 3Yahoo FinanceARQT
      Arcutis appoints Rob Scott to board of directors
      Oct 28Investing.comARQT
      Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
      Oct 28Yahoo FinanceARQT
      Arcutis Appoints Rob Scott, MD to Board of Directors
      Oct 28Yahoo FinanceARQT
      Arcutis Biotherapeutics director Welgus sells $127,325 in stock
      Oct 20Investing.comARQT
      Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb
      Oct 20Yahoo FinanceARQT
      Clinical Data Update Could Shape The Case For Arcutis Biotherapeutics Stock
      Oct 19Yahoo FinanceARQT
      Arcutis Biotherapeutics advances 11% to new 52-week high (ARQT:NASDAQ)
      Oct 19Seeking AlphaARQT
      Arcutis Soars 12% as Guggenheim Lifts Target to $44 on “Growing Conviction” in 2027
      Oct 19Yahoo FinanceARQT
      Arcutis Biotherapeutics stock hits 52-week high at $31.80
      Oct 19Investing.comARQT
      Why Is Arcutis Biotherapeutics Stock Surging Thursday?
      Oct 15BenzingaARQT
      Arcutis stock wins new Overweight at Cantor (ARQT:NASDAQ)
      Oct 15Seeking AlphaARQT
      Arcutis Biotherapeutics (ARQT) Showcased Fresh ZORYVE Data, Is It Still 28% Below Fair Value?

      What the new ZORYVE data means for Arcutis Biotherapeutics stock Arcutis Biotherapeutics (ARQT) just used two major dermatology conferences to showcase fresh clinical and real world data across its ZORYVE portfolio, putting the product suite, not macro headlines, at the center of the stock story. Investors now have more detail on how ZORYVE cream and foam are being studied across atopic dermatitis, plaque psoriasis and seborrheic dermatitis, as well as new research on long term topical...

      Oct 10Yahoo FinanceARQT
      Arcutis presents data on ZORYVE cream for infant eczema
      Oct 9Investing.comARQT
      Jefferies reiterates Arcutis stock Buy rating on Zoryve growth
      Oct 8Investing.comARQT
      Arcutis Biotherapeutics: An Emerging GARP Stock (NASDAQ:ARQT)
      Oct 6Seeking AlphaARQT
      Arcutis: Every Beat Gets Absorbed By A Shrinking Multiple (Rating Downgrade) (NASDAQ:ARQT)

      Arcutis Biotherapeutics' fair value is estimated at $24.41 per share, with upside contingent on clinical wins. Read why ARQT stock is downgraded to a hold.

      Oct 6Seeking AlphaARQT
      Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares
      Sep 18Investing.comARQT
      Arcutis Biotherapeutics director Welgus sells $114k in shares
      Sep 17Investing.comARQT
      Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

      Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

      Sep 17Yahoo FinanceARQT
      Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11%

      Key TakeawaysConference Pop: Arcutis Biotherapeutics stock jumped 11. 19% on September 16, closing at $26.

      Sep 17Yahoo FinanceARQTMS
      Arcutis at Morgan Stanley conference: zoryve drives growth push
      Sep 16Investing.comARQTMS
      Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock
      Sep 11Investing.comARQT
      Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
      Sep 2BarchartARQT
      Arcutis director Terrie Curran sells $956k in shares
      Aug 28Investing.comARQT
      Here's Why You Should Add ARQT Stock to Your Portfolio Now

      Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

      Aug 28The Globe and MailARQT
      Arcutis Biotherapeutics (ARQT) Faces A Valuation Test, Is It Still A Bargain?

      Arcutis Biotherapeutics Stock Performance Snapshot Arcutis Biotherapeutics (ARQT) has drawn investor attention after recent share price moves, with the stock down about 12% over the past month but up roughly 16% over the past 3 months. The company, which focuses on dermatological treatments such as its lead product ZORYVE, now carries a market value of about US$3.16b and recently closed at US$24.87 as of 25 August 2026. Looking at the bigger picture, Arcutis Biotherapeutics has seen mixed...

      Aug 28Yahoo FinanceARQT
      Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

      Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

      Aug 27Yahoo FinanceARQTHALOIOVAPGENRGEN
      Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18K
      Aug 25BenzingaARQT

      This is the newest page. Registered accounts read further back.